Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I Study of Fixed Dose Lapatinib in Combination With an Escalating Dose of Epirubicin in Metastatic Breast Cancer

NCT00753207 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT00753207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00753207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I Study of Fixed Dose Lapatinib in Combination With an Escalating Dose of Epirubicin in Metastatic Breast Cancer
Lead sponsor
Cancer Trials Ireland
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
March 31, 2012
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer